you, Matt. us. for and Good thank afternoon, all you joining Thank
existing future important product strategic the system sleek, state-of-the growth laser bringing engagement year. advance filed atherectomy and two imaging create features we new and our CTO-crossing Tigereye for submissions and ST year, our launched April, a also new new XXX(k) new FDA highly product image platform, peripheral which and and we our Lightbox opportunity to our moves and generation two exciting portfolio, our console, platform, We've capabilities for incorporates Pantheris for company. our to guided build In next with important a portable Over out the expanding accounts. to the provide opportunities launches into both which new past catheters, efficiencies benefits this peripheral portfolio made X technology for bring new art for LV
months, up made Over coronary for in in further fields development significant the the of a first product past our establishing intravascular crossing feedback CTO evaluation. design imaging, and Coronary of development and and interventional clinical several gaining important application, the highly of progress advisory experienced we've made on cardiologists board prototypes
even only Our the enthusiastic OCT-guided coronary system CTOs. revolutionize image work proprietary made our with the guided for for potential date market this has to to first about us approach crossing and more
solid cost reported margin continued our and to in improvement improving model operating we fourth During operating ago metrics, year quarter, the the gross period. compared driving
facility continue the shortages While we availability staffing itself lessened, crisis the and areas. impact effect to the see certain of COVID direct has in on of procedure
reduced capability. impacted turnover case sales by salesforce, fourth headcount directly in quarter more our coverage and was revenue to Our clinical leading
ago quarter productivity, XXXX, revenue revenue the of with the our head, measured declined year field fourth period. sales total remained in consistent by per While sales
our bringing new provided leveraging flexibility accounts we X five new available a companies total recruiting of year imaging added and new reduce larger specialists process the as of Lightbox console, to coverage case expand added in pool larger during to fourth their to by additional are our clinical talent of By the headcounts during beginning number are XX. capability to the markets in quarter, trim our see costs. We key accounts the
As and X with by now approximately we continue of gain more new physicians experience performance reliability XX XX with Lightbox in Lightbox has more platform. innovative been this used thrilled X, XXX accounts. than to we be cases in the
each rates to atherectomy well competitive sequential Pantheris positively continue on French image-guided is for Our trend a basis. attractive Avinger. Pantheris products the market, both SV a and X market perform and with our quarter that to with in continue Atherectomy Pantheris reimbursement X% devices growing growing
For reimbursement, Office decreased or X%. with row by and X% derived from Medicare XXXX, Labs, settings. has the This hospital hospital reimbursement widening OBL reimbursement the since the OBLs, the of Medicaid approximately as and gap reimbursement the a two XX% positive hospital Services, for is a for or between is our reimbursement second increasing see in Avinger, in decreasing We net Based atherectomy Centers and revenue approximately X% this in in to CMS, increased by outpatient year accounts.
small to device, SV in XXXX, be vessel Pantheris selling single a atherectomy now SKY. continues is and performer Our strong largest introduced our
vessels. patients narrow damage knee great primarily within millimeter these or provided disease critical Pantheris the SV lesions, excellent. the and benefit while precise by severe vascular population four most patient outcomes to Physicians CLI, to of rely this whom the to of ischemia arterial used to the treat when continue two with Pantheris limb precisely of diameter form on SV imaging control challenging Clinical treating below real-time be from to many the in is target lesions PAD. suffer structures, avoiding
world evaluate the for Image lesions BTK, document To to in of knee a a post clinical conducting results, these below study real setting. we're SV the treatment clinical market Pantheris called designed
the year. now enrollment expect Interim patients to have results outstanding. to approximately study enrolled We continue be complete this and in XX
XX% XX% patients freedom their and XX adverse visit. from enrolled the completing months residual post completing a stenosis a XX% end of XXX% average, to of to with XX% of stenosis than having a blockage stenosis SV with XX, This XX stenosis treatment. Treatment patients days. December events than X% of year. of less outcomes safety XX to of adjudicated duplex therapy. patient reduction at compelling, As month an had Performance alone procedure their XX% or subjects or this been On lesions ultrasound has six via average. adjunctive XXX% is revascularization stenosis so lab. index population longer prior less with of freedom at from by alone, increased on the core Most SV XX% therapy, study. been Pantheris patients patients major reduced Pantheris adjunctive XXX% in patency independent treatment against and excellent, XX% in exhibited Lesion residual visit the in for are study, with the XX the equally reported of the the months, far XX efficacy stenosis with after Primary lesions average At Target with have endpoints and having XX% only six exciting term TLR, post by
large results artery diameter mm is and the vessels without is second LV on vessel in XXXX, be of also a at from popliteal higher X These need rotational extremely January expand which launch in in half and this anatomy. plan device. be in majority patency X by commercial freedom designed to TLR and remarkable PAD balloon, Pantheris to lesions for the this showing XX% to XX with our where guidewire We treat enhances capabilities for our whom device to proving are plaque procedures filed allow significant of SFA and Truly procedural patient midyear challenging the to speeds treat the a FDA to that are performed. modified SV of design in months. results patients significantly would efficiency. management anatomy to and Pantheris Pantheris utilizes behind build operate atherectomy management XXX a this and durable, at in We and population, further this above anticipate many designed with our year. to It clearance LV, ideally knee procedure for design amputation. plaque principles otherwise suited LV Pantheris system risk the challenging XX% early Pantheris opposition is a would application success from proprietary streamline introduction new incorporates implements for key improve the (k) of LV and of and at the
third Tigereye ST new our In the filing, XXXX, Pantheris to new our (k) in peripheral for crossing LV the of we quarter CTO filed in addition catheter for a submission arteries. XXX
including While of their filings, and little FDA XXX standard clearance a longer lead requested all additional for longer device time documentation review some taken than this biocompatibility recent process. has part testing, we've as most by our provided (k) testing
still within takes this this We we open XXX normal XXX time. to frames our time eight requests are so submission clearance for our (k) (k) filing. Time have at months, typically on from four no submissions with our to
strength experience the new review to limited we of excited believe FDA in of are of clearance the this advanced data, gain making our process anticipate launch are FDA we are our and with Given basis clearance coming the weeks, an and preparations on completeness response we pending initiate end expedited nearing device. the and the that significantly to clinical
to increase enhancements for the the CTO in procedure. the platform Tigereye ST speeds in deflectable Tigereye treatment definition, ST for and incorporates real-time system, incorporates ST procedural tip controlled challenging the to guided rotational crossing the Tigereye provide design configuration to advanced interpretation catheter peripheral power is user capabilities to catheters shaft the disease. ease XXXX. By expand continues imaging, tip in addressable image and It the success to and new design lesions. image our upgrades also during to high expected of market of bringing faster introduced
believe commercial CTO our atherectomy excitement opportunities first device the will the platform our Pantheris of Taken the half of year in new crossing second of the and our case LV expand our together, for addressable launch year bring the and of we ST to Tigereye products. device in half launch anticipated
Combined with vascular console, catheters will opportunities leadership peripheral assert we for company. imaging X new technology space our our believe provide our these Lightbox and growth new the in new
very the chronic coronary image currently in to first the technology. of this technology market crossing By available and opportunity are a for in utilizing look the crossing the is a coronary future, reimbursement redefine challenging making market total large and development can for growing in with product occlusions we fully which our codes existing leveraging application, first we expensive we're platform, mover with the excited guided believe and we progress provides about we procedure CTOs. integrated arteries place, system innovation only As in first the our complex, proprietary coronary
allow time CTO coronary steerability integrated on development approach to safely an real guidance low precise OCT cross facilitate to coronary designs catheter and CTOs. Our with combine that efforts and profile are physicians control focused and efficiently
is which precise coronary for a with well scenario, We imaging coronary and attractive upon designed help catheters, for media FDA CTO An our that prior clearance. the less compelling believe placement, differentiating therapeutic our the device coronary peripheral economic to both provides support will optimal properly diagnostic with stents usage, outcomes. an Similar sized reimbursement combined the diagnostic devices guided OCT codes efficiency to opportunity or OCT fewer physicians need as highly existing access procedure and crossing contrast capabilities for crossing immediately for incorporate guided value critical image for measurement balloons with to devices for as reimbursement capability catheter highly a would proposition.
clinical CTO interventional are leaders of our intravascular we've a of guide opinion board To highly advisory experienced fields crossing efforts, imaging. key up coronary and made the established in who cardiologists development
and months, benchtop recently development today goal XXXX. animal XX to FDA advisors, several the a solution findings a we've feedback IDE filing months and a development clinical evaluate in of procedure. definite safety is with large to our for further what clinical and assessing in We program an market the of different excitement to with or in quarter, evaluated second past incredibly with of studies and an allow anticipate Exemption and is gaining difficult our initiation opportunity elegant There approaches the and next the study shared efficacy a around for meet our to design prototypes an the models, need device and Device the designs with Investigational important Over have evaluation.
XXXX. Given advancing coronary vast represented coronary development the CTO is by our product potential principal program for the markets, R&D
basis, execution in commercial area strategic to focused on a business. three is growth peripheral drive our On of we're
in of and sales First, training and core geographic increasing through case utilization capability the team. catheter coverage expansion our clinical areas our
for our the this Second, expanding new we driving in peripheral commercial process completing activity deployment X regulatory console. And base launch new which of our imaging user drivers approval our throughout for on of create new and program two appeal portfolio the our account through to new preparation initiatives broaden year, our on third, as will as and Lightbox you continued for devices the platform. progress well We product coronary our year. updating the usage forward believe development product look these
to the for our like Officer, Q&A. take I'd point, Accounting I'll return over call us this turn to financial Officer Financial the At through Nabeel? then Subainati, to and Nabeel results, Principal and
